Depleting IFIT2 mediates atypical PKC signaling to enhance the migration and metastatic activity of oral squamous cell carcinoma cells

Oncogene

Volumn 32, Issue 32, 2013, Pages 3686-3697

  Lai, K C ^a,b   Liu, C J ^c   Chang, K W ^d   Lee, T C ^b  

^a TZU CHI UNIVERSITY   (Taiwan)

^b INSTITUTE OF BIOMEDICAL SCIENCES   (Taiwan)

^c MACKAY MEMORIAL HOSPITAL   (Taiwan)

^d NATIONAL YANG MING UNIVERSITY   (Taiwan)

Author keywords

atypical PKC; epithelial mesenchymal transition; IFIT2; invasion; migration; oral squamous cell carcinoma

Indexed keywords

FIBRONECTIN; INTERFERON INDUCED PROTEIN WITH TETRATRICOPEPTIDE REPEAT; MESSENGER RNA; NERVE CELL ADHESION MOLECULE; PROTEIN KINASE C; SMALL INTERFERING RNA; TETRATRICOPEPTIDE REPEAT PROTEIN; UNCLASSIFIED DRUG; UVOMORULIN; VIMENTIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL CULTURE; CANCER PROGNOSIS; CANCER SURVIVAL; CELL INVASION; CELL MIGRATION; CELL MOTILITY; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DISTANT METASTASIS; DISTANT METASTASIS FREE SURVIVAL; ENZYME PHOSPHORYLATION; EPITHELIAL MESENCHYMAL TRANSITION; GENE EXPRESSION; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; METASTASIS; MOUSE; MOUTH SQUAMOUS CELL CARCINOMA; NONHUMAN; OVERALL SURVIVAL; PERINEURAL INVASION; PERITONEAL CAVITY; PHENOTYPE; PRIORITY JOURNAL; PROTEIN DEPLETION; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TUMOR GROWTH; TUMOR INVASION; WESTERN BLOTTING;

ANIMALS; BASE SEQUENCE; CADHERINS; CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; CELL MOVEMENT; EPITHELIAL-MESENCHYMAL TRANSITION; HUMANS; MICE; MOLECULAR SEQUENCE DATA; MOUTH NEOPLASMS; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; PROGNOSIS; PROTEIN KINASE C; PROTEINS; SIGNAL TRANSDUCTION;

EID: 84881477574     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2012.384     Document Type: Article

References (52)

1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005; 55: 74-108.
2. Department of Health, TEY. Cancer Registry Annual Report in Taiwan Area, 2008-2009. Department of Health, The Executive Yuan: Taiwan 2010.
3. Bagan JV, Scully C. Recent advances in Oral Oncology 2008; squamous cell carcinoma aetiopathogenesis and experimental studies. Oral Oncol 2009; 45: e45-e48.
4. Fan S, Tang QL, Lin YJ, Chen WL, Li JS, Huang ZQ et al. A review of clinical and histological parameters associated with contralateral neck metastases in oral squamous cell carcinoma. Int J Oral Sci 2011; 3: 180-191.
5. Leon X, Quer M, Diez S, Orus C, Lopez-Pousa A, Burgues J. Second neoplasm in patients with head and neck cancer. Head Neck 1999; 21: 204-210.
6. Shingaki S, Takada M, Sasai K, Bibi R, Kobayashi T, Nomura T et al. Impact of lymph node metastasis on the pattern of failure and survival in oral carcinomas. Am J Surg 2003; 185: 278-284.
7. Gonzalez-Garcia R, Naval-Gias L, Roman-Romero L, Sastre-Perez J, Rodriguez-Campo FJ. Local recurrences and second primary tumors from squamous cell carcinoma of the oral cavity: a retrospective analytic study of 500 patients. Head Neck 2009; 31: 1168-1180.
8. Rao DN, Shroff PD, Chattopadhyay G, Dinshaw KA. Survival analysis of 5595 head and neck cancers-results of conventional treatment in a high-risk population. Br J Cancer 1998; 77: 1514-1518.
9. Sano D, Myers JN. Metastasis of squamous cell carcinoma of the oral tongue. Cancer Metastasis Rev 2007; 26: 645-662.
10. Bell RB, Kademani D, Homer L, Dierks EJ, Potter BE. Tongue cancer: Is there a difference in survival compared with other subsites in the oral cavity? J Oral Maxillofac Surg 2007; 65: 229-236.
11. Cooper JS, Pajak TF, Forastiere AA, Jacobs J, Campbell BH, Saxman SB et al. Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neck. N Engl J Med 2004; 350: 1937-1944.
12. Friedl P, Wolf K. Tumour-cell invasion and migration: diversity and escape mechanisms. Nat Rev Cancer 2003; 3: 362-374.
13. Korsching E, Packeisen J, Liedtke C, Hungermann D, Wulfing P, van Diest PJ et al. The origin of vimentin expression in invasive breast cancer: epithelial-mesenchymal transition, myoepithelial histogenesis or histogenesis from progenitor cells with bilinear differentiation potential? J Pathol 2005; 206: 451-457.
14. Parri M, Chiarugi P. Rac and Rho GTPases in cancer cell motility control. Cell Commun Signal 2010; 8: 23.
15. Tsuji T, Ibaragi S, Hu GF. Epithelial-mesenchymal transition and cell cooperativity in metastasis. Cancer Res 2009; 69: 7135-7139.
16. Yang J, Weinberg RA. Epithelial-mesenchymal transition: at the crossroads of development and tumor metastasis. Dev Cell 2008; 14: 818-829.
17. Yilmaz M, Christofori G. EMT, the cytoskeleton, and cancer cell invasion. Cancer Metastasis Rev 2009; 28: 15-33.
18. Taki M, Kamata N, Yokoyama K, Fujimoto R, Tsutsumi S, Nagayama M. Downregulation of Wnt-4 and up-regulation of Wnt-5a expression by epithelialmesenchymal transition in human squamous carcinoma cells. Cancer Sci 2003; 94: 593-597.
19. Levy D, Larner A, Chaudhuri A, Babiss LE, Darnell Jr JE. Interferon-stimulated transcription: isolation of an inducible gene and identification of its regulatory region. Proc Natl Acad Sci USA 1986; 83: 8929-8933.
20. Terenzi F, Hui DJ, Merrick WC, Sen GC. Distinct induction patterns and functions of two closely related interferon-inducible human genes, ISG54 and ISG56. J Biol Chem 2006; 281: 34064-34071.
21. Saha S, Sugumar P, Bhandari P, Rangarajan PN. Identification of Japanese encephalitis virus-inducible genes in mouse brain and characterization of GARG39/IFIT2 as a microtubule-associated protein. J Gen Virol 2006; 87: 3285-3289.
22. Lai KC, Chang KW, Liu CJ, Kao SY, Lee TC. IFIT2 protein inhibits migration activity and increases survival in oral squamous cell carcinoma. Mol Cancer Res 2008; 6: 1-9.
23. Eger A, Aigner K, Sonderegger S, Dampier B, Oehler S, Schreiber M et al. DeltaEF1 is a transcriptional repressor of E-cadherin and regulates epithelial plasticity in breast cancer cells. Oncogene 2005; 24: 2375-2385.
24. Christiansen JJ, Rajasekaran AK. Reassessing epithelial to mesenchymal transition as a prerequisite for carcinoma invasion and metastasis. Cancer Res 2006; 66: 8319-8326.
25. Rosse C, Linch M, Kermorgant S, Cameron AJ, Boeckeler K, Parker PJ. PKC and the control of localized signal dynamics. Nat Rev Mol Cell Biol 2010; 11: 103-112.
26. Yonezawa T, Kurata R, Kimura M, Inoko H. PKC delta and epsilon in drug targeting and therapeutics. Recent Pat DNA Gene Seq 2009; 3: 96-101.
27. Polyak K, Weinberg RA. Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits. Nat Rev Cancer 2009; 9: 265-273.
28. Lin D, Edwards AS, Fawcett JP, Mbamalu G, Scott JD, Pawson T. A mammalian PAR-3-PAR-6 complex implicated in Cdc42/Rac1 and aPKC signalling and cell polarity. Nat Cell Biol 2000; 2: 540-547.
29. Suzuki A, Yamanaka T, Hirose T, Manabe N, Mizuno K, Shimizu M et al. Atypical protein kinase C is involved in the evolutionarily conserved par protein complex and plays a critical role in establishing epithelia-specific junctional structures. J Cell Biol 2001; 152: 1183-1196.
30. Etienne-Manneville S, Manneville JB, Nicholls S, Ferenczi MA, Hall A. Cdc42 and Par6-PKCzeta regulate the spatially localized association of Dlg1 and APC to control cell polarization. J Cell Biol 2005; 170: 895-901.
31. Etienne-Manneville S, Hall A. Cdc42 regulates GSK-3beta and adenomatous polyposis coli to control cell polarity. Nature 2003; 421: 753-756.
32. Etienne-Manneville S. Cdc42-the centre of polarity. J Cell Sci 2004; 117: 1291-1300.
33. Cross DA, Alessi DR, Cohen P, Andjelkovich M, Hemmings BA. Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B. Nature 1995; 378: 785-789.
34. Fang X, Yu SX, Lu Y, Bast Jr RC, Woodgett JR, Mills GB. Phosphorylation and inactivation of glycogen synthase kinase 3 by protein kinase A. Proc Natl Acad Sci USA 2000; 97: 11960-11965.
35. Sutherland C, Leighton IA, Cohen P. Inactivation of glycogen synthase kinase-3 beta by phosphorylation: new kinase connections in insulin and growth-factor signalling. Biochem J 1993; 296: 15-19.
36. Doble BW, Woodgett JR. GSK-3: tricks of the trade for a multi-tasking kinase. J Cell Sci 2003; 116: 1175-1186.
37. Doble BW, Woodgett JR. Role of glycogen synthase kinase-3 in cell fate and epithelial-mesenchymal transitions. Cells Tissues Organs 2007; 185: 73-84.
38. Mishra R. Glycogen synthase kinase 3 beta: can it be a target for oral cancer. Mol Cancer 2010; 9: 144.
39. Ma C, Wang J, Gao Y, Gao TW, Chen G, Bower KA et al. The role of glycogen synthase kinase 3beta in the transformation of epidermal cells. Cancer Res 2007; 67: 7756-7764.
40. Sanchez-Tillo E, Lazaro A, Torrent R, Cuatrecasas M, Vaquero EC, Castells A et al. ZEB1 represses E-cadherin and induces an EMT by recruiting the SWI/SNF chromatin-remodeling protein BRG1. Oncogene 2010; 29: 3490-3500.
41. Behrens J, Mareel MM, Van Roy FM, Birchmeier W. Dissecting tumor cell invasion: epithelial cells acquire invasive properties after the loss of uvomorulin-mediated cell-cell adhesion. J Cell Biol 1989; 108: 2435-2447.
42. Schmalhofer O, Brabletz S, Brabletz T. E-cadherin beta-catenin, and ZEB1 in malignant progression of cancer. Cancer Metastasis Rev 2009; 28: 151-166.
43. Ohira T, Gemmill RM, Ferguson K, Kusy S, Roche J, Brambilla E et al. WNT7a induces E-cadherin in lung cancer cells. Proc Natl Acad Sci USA 2003; 100: 10429-10434.
44. Minn AJ, Kang Y, Serganova I, Gupta GP, Giri DD, Doubrovin M et al. Distinct organ-specific metastatic potential of individual breast cancer cells and primary tumors. J Clin Invest 2005; 115: 44-55.
45. Lu X, Kang Y. Organotropism of breast cancer metastasis. J Mammary Gland Biol Neoplasia 2007; 12: 153-162.
46. Lorusso G, Ruegg C. New insights into the mechanisms of organ-specific breast cancer metastasis. Semin Cancer Biol 2012; 22: 226-233.
47. Ferlito A, Rinaldo A, Buckley JG, Mondin V. General considerations on distant metastases from head and neck cancer. ORL J Otorhinolaryngol Relat Spec 2001; 63: 189-191.
48. Sanjiv K, Su TL, Suman S, Kakadiya R, Lai TC, Wang HY et al. The novel DNA alkylating agent BO-1090 suppresses the growth of human oral cavity cancer in xenografted and orthotopic mouse models. Int J Cancer 2011; 130: 1440-1450.
49. Wiznerowicz M, Trono D. Conditional suppression of cellular genes: lentivirus vector-mediated drug-inducible RNA interference. J Virol 2003; 77: 8957-8961.
50. Chang SY, Su PF, Lee TC. Ectopic expression of interleukin-1 receptor type II enhances cell migration through activation of the pre-interleukin 1alpha pathway. Cytokine 2009; 45: 32-38.
51. Kim DW. Real time quantitative PCR. Exp Mol Med 2001; 33: 101-109.
52. Albini A, Iwamoto Y, Kleinman HK, Martin GR, Aaronson SA, Kozlowski JM et al. A rapid in vitro assay for quantitating the invasive potential of tumor cells. Cancer Res 1987; 47: 3239-3245.